However, when allowed to develop further in combination with Apc and Kras mutations, these models go on to upregulate several intrinsic (tumour cell autonomous) and extrinsic (TME-driven) signatures (CRIS-B and CMS4) associated with aggressive later-stage CRC. This evidence concerns the gene KRAS and neoplasm.